The latest special series from JITC, COVID-19 and Cancer Immunotherapy, is a set of authoritative reviews that serves as a valuable resource illustrating the impact COVID-19 has on cancer patients undergoing immunotherapy, providing guidance on clinical decision-making, and offering insights on the use of immunotherapy to treat COVID-19 manifestations. In addition to this special series, JITC continues to publish COVID-related cancer immunotherapy articles in the COVID-19 Collection.
Explore Collections.
The Journal for ImmunoTherapy of Cancer
is an open access journal that publishes high quality research, literature reviews, position papers and practice guidelines, and case studies on all components of cancer immunology and immunotherapy.
Impact Factor: 13.751
Citescore: 10.4
All metrics >>
The Journal for ImmunoTherapy of Cancer (JITC) aims to enrich communication and advance scientific understanding in the rapidly evolving fields of tumor immunology and cancer immunotherapy. Topics of interest range across the basic science-translational-clinical spectrum and include tumor-host interactions, the tumor microenvironment, animal models, predictive and prognostic immune biomarkers, novel pharmaceutical and cellular therapies, vaccines, combination immune-based therapies, and immune-related toxicity.
As a way to say thank you to the dedicated Society for Immunotherapy of Cancer (SITC) members who tirelessly work to advance the science and improve the lives of patients with cancer, SITC will provide members with a 50% discount on article processing charges for all member-authored 2022 publications.
EDITOR-IN-CHIEF
Pedro J. Romero, MD, University of Lausanne
Editorial Board
